Breaking News

Financial Report: AbbVie

July 25, 2014

Humira sales up 10% in the quarter


2Q Revenues: $4.9 billion (+5%)

2Q Earnings: $1.1 billion (+3%)

YTD Revenues: $9.5 billion (+5%)

YTD Earnings: $2.1 billion (+2%)

Comments: Humira sales were up 10% to $3.3 billion in the quarter. AndroGel sales reached $218 million. Synthroid ($166 million), Sevoflurane ($154 million, +11%) and Duodopa ($56 million, +29%) also performed well in the quarter. Kaletra sales dropped 24% to $216 million and Lupron sales were down 3% to $186 million. The company recently announced plans to merge with Shire, creating a larger and more diversified biopharma company with multiple leading franchises.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments